Adagio Medical Raises $42.5 Million In Series E Financing

LAGUNA HILLS, Calif., Nov. 12, 2020 /PRNewswire/ -- Adagio Medical, Inc., a leading innovator for the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), and developer of the intelligent Continuous Lesion Ablation System (iCLAS™), today announced that it has closed a $42.5 million Series E equity financing.  Proceeds from the financing will be used to support [...]

2020-11-17T07:53:44-08:00November 17th, 2020|

Adagio Medical, Inc., reports pre-clinical effectiveness combining their existing ultra-low temperature cryoablation catheter with Pulsed Field Ablation (PFA) in a single Pulsed Field Cryoablation (PFCA) catheter

LAGUNA HILLS, Calif., August 3, 2020 /PRNewswire/ --Adagio Medical, Inc., a leading innovator for the treatment of atrial fibrillation (AFib) and ventricular tachycardia (VT), and developer of the intelligent Continuous Lesion Ablation System (iCLAS™), today announced successful pre-clinical results demonstrating their existing cryoablation catheter is also capable of ablating the tissue through pulsed field ablation (PFA) delivered [...]

2020-08-04T08:40:44-07:00August 3rd, 2020|

Adagio Medical Receives CE Mark Approval for its iCLAS™ Cryoablation System and Prepares for European Commercial Launch

LAGUNA HILLS, Calif., June 1, 2019 /PRNewswire/ --Adagio Medical, Inc., announces that it has received CE Mark approval for its ultra-low temperature intelligent Continuous Lesion Ablation System (iCLAS) for the endocardial treatment of paroxysmal (PAF) and persistent (PsAF) atrial fibrillation and atrial flutter. "More than half of all atrial fibrillation (AF) patients are diagnosed with PsAF. There [...]

2020-06-02T10:30:47-07:00June 1st, 2020|

Adagio Medical Announces First Patient Enrollment in its iCLAS™ U.S. IDE Clinical Trial Evaluating Ultra-Low Temperature Cryoablation for Persistent Atrial Fibrillation

LAGUNA HILLS, Calif., Dec. 16, 2019 /PRNewswire/ -- Adagio Medical, Inc. (Adagio) today announced it has enrolled the first patient in its iCLAS™ Investigational Device Exemption (IDE) trial.  The FDA approved study aims to evaluate the safety and efficacy of Adagio's ultra-low temperature intelligent Continuous Lesion Ablation System (iCLAS) in the treatment of persistent atrial fibrillation (PsAF).  Data [...]

2019-12-17T14:03:00-08:00December 16th, 2019|

Adagio Medical Announces US FDA Investigational Device Exemption Approval With Conditions To Conduct A Clinical Study For Treatment Of Persistent Atrial Fibrillation Using The Ultra-Low Temperature Cryoablation System

LAGUNA HILLS, Calif., Aug. 19, 2019 /PRNewswire/ -- Adagio Medical, Inc. (Adagio), the developer of iCLAS™, the company's ultra-low temperature intelligent continuous lesion ablation system, announced that it has received an Investigational Device Exemption approval with conditions from the US Food and Drug Administration (FDA) to conduct a non-randomized, single-arm clinical study for persistent atrial fibrillation (AF). [...]

2019-08-20T00:30:21-07:00August 19th, 2019|

Adagio Medical Treats First Persistent Atrial Fibrillation Patient With One Shot+™ Cryoablation Catheter Utilizing Only Anatomical Markers For Accurate Imaging

LAGUNA HILLS, Calif., July 31, 2019 /PRNewswire/ -- Adagio Medical, Inc., the developer of iCLAS™, the company's ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces that the first PsAF patient was successfully treated with its new One Shot+™ cryoablation catheter in a procedure that utilizes only anatomical markers with limited [...]

2019-07-31T15:13:15-07:00July 31st, 2019|

Adagio Medical’s Persistent Atrial Fibrillation Cryoablation Study Demonstrates Early Single-Treatment Results Superior To Ablation Devices Requiring Two Procedures

LAGUNA HILLS, Calif., Nov. 28, 2018 /PRNewswire/ -- Adagio Medical, Inc., developer of the iCLAS™ technology, the company's ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces updates to its ongoing cryoablation study for Persistent Atrial Fibrillation (PsAF). The study is currently being conducted at two clinical sites in Europe and two [...]

2018-11-28T15:02:40-08:00November 28th, 2018|

Adagio Medical Completes Chronic Pre-Clinical Atrial Fibrillation Study Using Ultra-Low Temperature Cryoablation Technology

Multiple Transmural, Continuous and Durable Lesions Created in Both Atria LAGUNA HILLS, Calif., Oct. 4, 2018 /PRNewswire/ -- Adagio Medical, Inc., the developer of the iCLAS™ technology, the company's ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces the successful completion of its chronic atrial fibrillation animal study, performed in collaboration [...]

2018-10-15T12:58:15-07:00October 4th, 2018|

Adagio Medical Treats First Atrial Fibrillation Patients Using New One Shot+™ Cryoablation Catheter

Simplified Procedure for Achieving Pulmonary Vein Isolation (PVI) with a Single Continuous Transmural Lesion LAGUNA HILLS, Calif., Oct. 1, 2018 /PRNewswire/ -- Adagio Medical, Inc., the developer of the iCLAS™ technology, the company's ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces that the first patients were successfully treated with its new [...]

2018-10-15T13:02:35-07:00October 1st, 2018|

First Three Persistent Atrial Fibrillation Patients Enrolled In Adagio Medical CryoCure Study Using Cryolinear Ablation Technology

LAGUNA HILLS, Calif., May 9, 2017 /PRNewswire/ -- Adagio Medical, Inc., the developer of a cryolinear ablation technology platform for the treatment of cardiac arrhythmias, announces that the first three persistent atrial fibrillation patients were treated in May 2017 using its technology.  This milestone follows the successful treatment of more than 25 arrhythmia patients in the [...]

2018-10-15T13:06:17-07:00May 9th, 2017|
Go to Top